Loading stock…

Abbott Laboratories (ABT) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Abbott Laboratories

ABTMarket cap $171BPrice $98.7

Country🇺🇸United States

SectorHealthcare

IndustryHealthcare Equipment

Abbott makes medical devices, diagnostics, and nutrition products that keep people alive and healthy worldwide. Their glucose monitors help 7 million diabetics manage blood sugar, while their heart devices beat inside millions of chests.

In Bastion Portfolios?

52W Return-22%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+1%3

Revenue Forecast

Rev CAGR (1y)+13%7

Rev CAGR (3y)+10%7

Rev CAGR (5y)+9%7

Earnings Forecast

EPS Growth Y+1+50%9

EPS Growth Y+2+10%6

EPS Growth Y+3+11%7

Quality

Margins

EBIT Margin18%7

Net Income Margin12%6

Free Cash Flow Margin17%7

Debt

Net Debt/EBITDA2.24

Efficiency

ROE11%5

ROA6%6

Earnings Stability44

GEAR+STRONG78

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)175

P/E Ratio (Forward 3y)155

P/BV3.34

EV Multiples

EV/EBITDA Fwd154

EV/EBIT Fwd175

Yield

Free Cash Flow Yield4.6%6

Dividend Yield2.6%6

Momentum

Short term

1 month return-6%4

3 month return+4%7

YTD return-20%2

Mid term

Price vs 52wHigh75%4

1 year return-25%2

Long term

3 year return+8%3

5 year return-8%3

Risk Shield

Price Risk

Beta0.110

Volatility27%8

Free Cash Flow

Free Cash Flow Margin17%7

Free Cash Flow Yield4.6%6

Quality

ROCE10%6

Earnings Stability44

Net Debt/EBITDA2.24

02Growth

Is it actually growing, and how fast?

ABTAbbott Laboratories

Revenue FY25$44.3B

GROWTH RATING↗

AVERAGE64 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+1%3

Revenue, next 1Y+13%7

Revenue, next 3Y, CAGR+10%7

Revenue, next 5Y, CAGR+9%7

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+50%9

EPS growth, FY27E+10%6

EPS growth, FY28E+11%7

GROWTH ASSESSMENT

STRENGTHS

Revenue is set to grow 10%/yr over the next 3 years, ahead of most of the market.7/10

Revenue grew 0.5%/yr over the last 3 years and is set to grow 10%/yr from here.

The runway holds up: revenue is set to grow 9%/yr over five years.7/10

Earnings are set to grow in step with sales (EPS about 11%/yr vs revenue 10%/yr).

WATCH

A mid-pack grower, ahead of 64% of companies worldwide.

WEAKNESSES

Revenue grew 0.5%/yr over the last 3 years, behind 70% of companies worldwide.3/10

BOTTOM LINE

Reaccelerating Grower

A middle-of-the-pack grower that's speeding up. The one thing to watch: the 3-year revenue record is weak.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

WEAK24 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-6%4

3-month return+4%7

YTD return-20%2

MID & LONG-TERM▾SCORE

% of 52-week high75%4

1-year return-25%2

3-year return+8%3

5-year return-8%3

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over three months (+4%).

WATCH

Returns sit at the market level over the past month (-6%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+8.5% over three years and -8.1% over five), behind 70% of the market.

It's down 25% over the past year, now 25% below its 52-week high. That is lagging the market.

The stock is underperforming so far this year (-20%).

BOTTOM LINE

Weak Tape

Returns across short and long horizons rank poorly versus the market. Momentum offers no support here; the case has to come from other factors. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Abbott. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

ABTAbbott Laboratories

Revenue FY25$44.3B

GROWTH RATING↗

AVERAGE64 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+1%3

Revenue, next 1Y+13%7

Revenue, next 3Y, CAGR+10%7

Revenue, next 5Y, CAGR+9%7

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+50%9

EPS growth, FY27E+10%6

EPS growth, FY28E+11%7

GROWTH ASSESSMENT

STRENGTHS

Revenue is set to grow 10%/yr over the next 3 years, ahead of most of the market.7/10

Revenue grew 0.5%/yr over the last 3 years and is set to grow 10%/yr from here.

The runway holds up: revenue is set to grow 9%/yr over five years.7/10

Earnings are set to grow in step with sales (EPS about 11%/yr vs revenue 10%/yr).

WATCH

A mid-pack grower, ahead of 64% of companies worldwide.

WEAKNESSES

Revenue grew 0.5%/yr over the last 3 years, behind 70% of companies worldwide.3/10

BOTTOM LINE

Reaccelerating Grower

A middle-of-the-pack grower that's speeding up. The one thing to watch: the 3-year revenue record is weak.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

WEAK24 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-6%4

3-month return+4%7

YTD return-20%2

MID & LONG-TERM▾SCORE

% of 52-week high75%4

1-year return-25%2

3-year return+8%3

5-year return-8%3

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over three months (+4%).

WATCH

Returns sit at the market level over the past month (-6%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+8.5% over three years and -8.1% over five), behind 70% of the market.

It's down 25% over the past year, now 25% below its 52-week high. That is lagging the market.

The stock is underperforming so far this year (-20%).

BOTTOM LINE

Weak Tape

Returns across short and long horizons rank poorly versus the market. Momentum offers no support here; the case has to come from other factors. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Abbott. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community